Chemotherapy Drug Manufactured by Venus Remedies | Available in the UK

For any drugs or medicine to be sold in a country, the company first needs to gain market authorizations. Market authorizations, also known as marketing authorizations or regulatory approvals, are the formal approvals granted by regulatory authorities to allow the marketing and sale of pharmaceutical products, medical devices, or other healthcare products in a specific country or region. These authorizations are typically granted after a rigorous review process to ensure the safety, efficacy, and quality of the product.

The process of obtaining market authorization involves submitting comprehensive data on the product's manufacturing, preclinical studies, clinical trials, and other relevant information to the regulatory authority. The authority then assesses the data to evaluate the product's benefits, risks, and overall quality. This evaluation includes a thorough examination of the product's safety profile, its intended use, the proposed labelling, and the manufacturing and quality control processes. Once a product receives market authorization, the company or organization can legally market and distribute the product in the approved country or region. Market authorizations are typically subject to ongoing monitoring and regulatory oversight to ensure continued compliance with safety and quality standards. This establishes the importance of market authorization as it acts as a green light that helps place effective and safe medication in the hands of the general public.

That being said, in recent times, Venus has managed to receive market authorization from the UK for Cisplatin. With the drug now available to be used as a first line of treatment for advanced ovarian and testicular cancer and bladder carcinoma, we can now provide affordable cancer drugs to the National Health Service in the UK and its neighbouring countries.

Over the years, Venus has managed to secure over 800 market authorizations from around the world. The addition of the UK market further establishes the success of the good work of the organisation. Various new articles by CNBCTV18, Financial Expres, India Times and Express Pharma, have covered this achievement, validating the impact that our organisation is having on the world and the lives of the people.

In addition to this Venus has also managed to market authorization for other products like Pemetrexed venus and Cytomib in Oman, CEFATOR 2000 IV in Mail, PARA-LUX 1000mg in Togo, Oxlatiplatin, Paclitaxel Docetaxel, Gemcitabine and Ceftriaxone in the Phillippines. Each of these market authorizations serves as a testament to the rigours and unyielding of the Venus researcher who tirelessly has strived to create medication that is affordable and effective.

We are grateful to all the Venusians who have dedicated themselves to achieving such a monumental feat. It is their passion and hard work which uphold the shining reputation that Venus has garnered through the eyes of the public. Similarly, thank the support of our stakeholders, who have motivated, supported and pushed us to achieve our goals. Moving forward, we shall take today’s achievement as inspiration to make further and greater milestones a reality in our mission to heal the people and make the future a healthier place to live.